Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody<sup>®</sup> Molecules <sup>177</sup>Lu-ABY-271 and <sup>177</sup>Lu-ABY-027: Impact of DOTA Position on ABD Domain

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody<sup>®</sup> Molecules <sup>177</sup>Lu-ABY-271 and <sup>177</sup>Lu-ABY-027: Impact of DOTA Position on ABD Domain

Radiolabeled Affibody-based targeting agent <sup>177</sup>Lu-ABY-027, a fusion of an anti-HER2 Affibody molecule with albumin binding domain (ABD) site-specifically labeled at the C-terminus, has demonstrated a promising biodistribution profile in mice; binding of the construct to albumi...

Full description

Bibliographic Details
Main Authors: Yongsheng Liu, Anzhelika Vorobyeva, Tianqi Xu, Anna Orlova, Annika Loftenius, Theresa Bengtsson, Per Jonasson, Vladimir Tolmachev, Fredrik Y. Frejd
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Pharmaceutics
Subjects:
affibody molecule
albumin binding domain (ABD)
<sup>177</sup>Lu
scaffold protein
radionuclide therapy
SKOV-3 xenograft
Online Access:https://www.mdpi.com/1999-4923/13/6/839

Similar Items

Similar Items